| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
7,227 |
4,866 |
$439K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
8,529 |
6,242 |
$392K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
4,525 |
3,386 |
$312K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,705 |
1,901 |
$261K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
6,989 |
4,384 |
$188K |
| 99051 |
|
6,620 |
5,425 |
$33K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,975 |
710 |
$13K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,045 |
808 |
$8K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
138 |
121 |
$7K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
193 |
156 |
$4K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
32 |
27 |
$1K |
| 92552 |
|
20 |
13 |
$166.14 |
| 99173 |
|
23 |
15 |
$114.00 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
19 |
13 |
$92.40 |
| 36416 |
|
23 |
15 |
$52.05 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
19 |
13 |
$3.91 |
| 99072 |
|
1,642 |
1,348 |
$0.00 |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
106 |
81 |
$0.00 |
| 81002 |
|
45 |
40 |
$0.00 |
| 99000 |
|
6,202 |
5,204 |
$0.00 |
| 85018 |
|
48 |
29 |
$0.00 |